Valencia, CA-based radioisotope development company Nusano has launched commercial operations and announced a lutetium-177 (Lu-177) supply agreement with Australian targeted radiotherapy company GlyTherix.
The agreement provides GlyTherix access to Nusano’s future actinium-225 (Ac-225) production, currently scheduled to begin in 2026, and planned future production of zirconium-89, lead-212, and terbium-161, Nusano said. GlyTherix is developing a radiopharmaceutical that combines Lu-177 with an antibody that targets Glypican-1, a protein found in aggressive cancers, with plans to launch a phase I trial this year.
Nusano said it will add isotopes to its product portfolio as additional capabilities come online at its flagship facility in West Valley City, UT. Under full operations, the facility will be capable of producing more than 25 radioisotopes applicable to the life sciences industry, with the simultaneous production of up to 12 different radioisotopes, the company noted.
